请输入您要查询的百科知识:

 

词条 Ergotamine
释义

  1. Mechanism of action

  2. Biosynthesis

  3. Drug uses

  4. Availability and dosage

  5. Side effects

  6. Additional Information

  7. See also

  8. References

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443732840
| IUPAC_name = (6aR,9R)-N-((2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
| image = Ergotamine-skeletal.svg
| width = 250
| image2 = Ergotamine ball-and-stick.png
| tradename = Cafergot, Ergomar
| Drugs.com = {{drugs.com|monograph|ergomar}}
| pregnancy_US = X
| pregnancy_category =
| legal_AU = Schedule 4
| legal_CA = Schedule VI
| legal_UK = POM
| legal_US = Rx-only
| legal_US_comment = DEA controlled precursor
| routes_of_administration = Oral
| bioavailability = Intravenous: 100%,[1]
Intramuscular: 47%,[2]
Oral: <1%[3] (Enhanced by co-administration of caffeine[1])
| metabolism = Hepatic[2]
| elimination_half-life = 2 hours[2]
| excretion = 90% biliary[2]
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 113-15-5
| ATC_prefix = N02
| ATC_suffix = CA02
| PubChem = 8223
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 64318
| IUPHAR_ligand = 149
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00696
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7930
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PR834Q503T
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07906
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 442
| PDB_ligand = ERM
| C=33 | H=35 | N=5 | O=5
| molecular_weight = 581.66 g/mol
| smiles = C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XCGSFFUVFURLIX-VFGNJEKYSA-N
}}

Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor.

It is used medicinally for treatment of acute migraine attacks (sometimes in combination with caffeine). Medicinal usage of ergot fungus began in the 16th century to induce childbirth, yet dosage uncertainties discouraged the use. It has been used to prevent post-partum hemorrhage (bleeding after childbirth). It was first isolated from the ergot fungus by Arthur Stoll at Sandoz in 1918 and marketed as Gynergen in 1921.[4]

Mechanism of action

The mechanism of action of ergotamine is complex.[5] The molecule shares structural similarity with neurotransmitters such as serotonin, dopamine, and epinephrine and can thus bind to several receptors acting as an agonist. The anti-migraine effect is due to constriction of the intracranial extracerebral blood vessels through the 5-HT1B receptor, and by inhibiting trigeminal neurotransmission by 5-HT1D receptors. Ergotamine also has effects on the dopamine and norepinephrine receptors.

Biosynthesis

Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae.[6] Its biosynthesis in these fungi requires the amino acid L-tryptophan and dimethylallyl diphosphate. These precursor compounds are the substrates for the enzyme, tryptophan dimethylallyltransferase, catalyzing the first step in ergot alkaloid biosynthesis, i.e., the prenylation of L-tryptophan. Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is the substrate of lysergyl peptide synthetase, a nonribosomal peptide synthetase, which covalently links LA to the amino acids, L-alanine, L-proline, and L-phenylalanine. Enzyme-catalyzed or spontaneous cyclizations, oxygenations/oxidations, and isomerizations at selected residues precede, and give rise to, formation of ergotamine.[7]

Drug uses

Ergotamine produces vasoconstriction peripherally as well as damages the peripheral epithelium. In high doses, ergotamine is conducive to vascular stasis, thrombosis, and gangrene. It can increase uterine contractivity and occasionally is used therapeutically immediately post-partum to decrease uterine bleeding. See also ergometrine.

Ergotamine continues to be prescribed for migraines. The common form of prescription is Cafergot which is a combination of caffeine and ergotamine.

Contraindications include: atherosclerosis, Buerger's syndrome, coronary artery disease, hepatic disease, pregnancy, pruritus, Raynaud's syndrome, and renal disease.[8]

It's also contraindicated if patient is taking Macrolide antibiotics (eg, erythromycin), certain HIV protease inhibitors (eg, ritonavir, nelfinavir, indinavir), certain azole antifungals (eg, ketoconazole, itraconazole, voriconazole) delavirdine, efavirenz or a 5-HT1 agonist (eg, sumatriptan).

[9]

Availability and dosage

In the United States, ergotamine is available as a suppository, a sublingual tablet, and a tablet, sometimes in combination with caffeine. The suppository is available under the brand name Migergot, which contains 2 mg of ergotamine with 100 mg caffeine. The sublingual tablet is available under the brand name Ergomar and contains 2 mg of ergotamine. The combination tablet in combination with caffeine called Cafergot contains 1 mg of ergotamine and 100 mg of caffeine.[10]

This preparation may be used immediately following the aura/onset of pain to abort the migraine. For the best results, dosage should start at the first sign of an attack.[11]

Side effects

Side effects of ergotamine include nausea and vomiting. At higher doses, it can cause raised arterial blood pressure, vasoconstriction (including coronary vasospasm) and bradycardia or tachycardia. Severe vasoconstriction may cause symptoms of intermittent claudication.[12]

Additional Information

Ergotamine is a controlled substance in the United States as it is a commonly used precursor for the production of LSD.[13]

See also

  • Dihydroergotamine, a semi-synthetic form used as an abortive migraine treatment
  • Ergotism
  • Ergometrine

References

1. ^{{cite journal|last=Sanders|first=SW|author2=Haering N |author3=Mosberg H |author4=Jaeger H |title=Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing|journal=Eur J Clin Pharmacol|date=1986|volume=30|issue=3|pages=331–4|doi=10.1007/BF00541538|pmid=3732370}}
2. ^Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 313–22.
3. ^Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16: 695–9.
4. ^AJ Giannini, AE Slaby. Drugs of Abuse. Oradell, NJ, Medical Economics Books, 1989.
5. ^{{cite journal |vauthors=Walkembach J, Brüss M, Urban BW, Barann M |title=Interactions of metoclopramide and ergotamine with human 5-HT3A receptors and human 5-HT reuptake carriers |journal=Br. J. Pharmacol. |volume=146 |issue=4 |pages=543–52 |date=October 2005 |pmid=16041395 |pmc=1751187 |doi=10.1038/sj.bjp.0706351}}
6. ^{{cite web|url=http://pharmaxchange.info/press/2011/12/pharmacognosy-of-ergot-argot-or-st-anthonys-fire/|title=Pharmacognosy of Ergot (Argot or St. Anthony's Fire) - Notes - PharmaXChange.info|author=|date=30 December 2011|website=pharmaxchange.info|deadurl=no|archiveurl=https://web.archive.org/web/20120717232322/http://pharmaxchange.info/press/2011/12/pharmacognosy-of-ergot-argot-or-st-anthonys-fire/|archivedate=17 July 2012|df=}}
7. ^{{cite book|vauthors=Schardl CL, Panaccione DG, Tudzynski P |year=2006|title=Ergot alkaloids--biology and molecular biology|journal= Alkaloids Chem. Biol.|volume=63|pages=45–86|pmid=17133714|doi=10.1016/S1099-4831(06)63002-2|series=The Alkaloids: Chemistry and Biology|isbn=978-0-12-469563-4}}
8. ^AJ Giannini. Biological Foundations of Clinical Psychiatry. Oradell, NJ. Medical Economics Puclishing Co., 1986.
9. ^{{cite web|title=Ergotamine: Indications, Side Effects, Warnings - Drugs.com|url=https://www.drugs.com/cdi/ergotamine.html|website=Drugs.com|accessdate=25 March 2017|deadurl=no|archiveurl=https://web.archive.org/web/20170325202114/https://www.drugs.com/cdi/ergotamine.html|archivedate=25 March 2017|df=}}
10. ^FDA Orange Book {{cite web |url=http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm |title=Archived copy |accessdate=2015-12-02 |deadurl=no |archiveurl=https://web.archive.org/web/20160817081251/http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm |archivedate=2016-08-17 |df= }}
11. ^{{cite web|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4a06de6-f837-43a8-ae7a-aadb38dd2a7d#DA|title=DailyMed - CAFERGOT- ergotamine tartrate and caffeine tablet, film coated|author=|date=|website=dailymed.nlm.nih.gov|deadurl=no|archiveurl=https://web.archive.org/web/20140116115705/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4a06de6-f837-43a8-ae7a-aadb38dd2a7d#DA|archivedate=2014-01-16|df=}}
12. ^{{cite web|url=https://www.drugs.com/pro/medihaler-ergotamine.html|title=Medihaler Ergotamine|website=drugs.com|accessdate=2016-05-20|deadurl=no|archiveurl=https://web.archive.org/web/20160401081841/http://www.drugs.com/pro/medihaler-ergotamine.html|archivedate=2016-04-01|df=}}
13. ^https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf
{{Ergolines}}{{Antimigraine preparations}}{{Adrenergic agonists}}{{Serotonergics}}

8 : Antimigraine drugs|Alpha-adrenergic agonists|Ergot alkaloids|Lactams|Oxazolopyrrolopyrazines|Lysergamides|Vasoconstrictors|Biased ligands

随便看

 

开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。

 

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间:2024/9/27 9:30:03